Loading...
XSHE000908
Market cap556mUSD
Jan 10, Last price  
4.64CNY
1D
-2.11%
1Q
23.73%
Jan 2017
-55.60%
Name

Hunan Jingfeng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000908 chart
P/E
—
P/S
6.21
EPS
—
Div Yield, %
0.58%
Shrs. gr., 5y
—
Rev. gr., 5y
-23.97%
Revenues
657m
-21.86%
258,565,213214,423,001237,627,852187,731,103216,801,752236,376,147217,389,628139,030,825145,267,112167,307,8851,957,430,0132,459,038,6812,640,503,6292,583,652,3352,585,696,9011,344,029,111877,918,599811,183,491840,657,161656,893,837
Net income
-215m
02,973,7102,728,1495,653,952002,991,727003,369,095251,029,269324,101,704340,028,576162,085,589186,812,6600000-215,144,077
CFO
35m
-71.55%
0057,903,24152,264,93031,015,808000351,5010205,930,47092,367,54912,324,621151,650,408350,937,84536,170,4280123,834,599123,266,70135,063,943
Dividend
Aug 23, 20180.01 CNY/sh
Earnings
May 30, 2025

Profile

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. The company was founded in 2003 and is headquartered in Shanghai, China.
URL
http://www.jfyiyao.com/
IPO date
Feb 03, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
656,894
-21.86%
840,657
3.63%
Cost of revenue
651,404
716,490
Unusual Expense (Income)
NOPBT
5,490
124,167
NOPBT Margin
0.84%
14.77%
Operating Taxes
32,835
10,332
Tax Rate
598.12%
8.32%
NOPAT
(27,345)
113,835
Net income
(215,144)
 
Dividends
(23,612)
Dividend yield
0.83%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
195,823
516,455
Long-term debt
117,656
92,204
Deferred revenue
20,730
24,808
Other long-term liabilities
69,814
58,928
Net debt
255,590
376,810
Cash flow
Cash from operating activities
35,064
123,267
CAPEX
(10,420)
Cash from investing activities
221,731
Cash from financing activities
(192,978)
FCF
709,185
282,416
Balance
Cash
13,165
181,392
Long term investments
44,724
50,456
Excess cash
25,044
189,816
Stockholders' equity
6,687
1,163,844
Invested Capital
200,237
660,514
ROIC
13.52%
ROCE
2.56%
14.53%
EV
Common stock shares outstanding
879,935
879,774
Price
3.24
1.89%
3.18
-27.06%
Market cap
2,850,989
1.91%
2,797,682
-27.06%
EV
3,002,393
3,211,393
EBITDA
49,950
179,573
EV/EBITDA
60.11
17.88
Interest
39,932
52,404
Interest/NOPBT
727.38%
42.20%